Reports Q2 revenue $325,000 vs. $3.02M last year. “We have continued to advance TRV045 in the second quarter,” said Carrie Bourdow, President and CEO of Trevena. “We believe the most recent data further supports TRV045’s therapeutic potential and differentiated MOA and its potential to address the need for novel, non-opioid therapies for treating neuropathic pain and epilepsy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVN:
- Trevena Reports Second Quarter 2024 Results and Provides Business Update
- Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
- Trevena announces $2M non-dilutive financing tranche
- Trevena announces preclinical data on TRV045 in two research collaborations
- Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models